GRIA2 encodes the GluA2 subunit of AMPA-type glutamate receptors, which function as ligand-gated cation channels that mediate fast excitatory synaptic transmission in the central nervous system 1. The GluA2 subunit has a unique regulatory role because post-transcriptional RNA editing at the Q607 site renders heteromultimeric AMPARs containing GluA2 relatively calcium-impermeable and creates a linear current-voltage relationship 1. However, recent evidence shows that GluA2-containing AMPARs actually form a continuum of calcium permeability that varies with subunit composition and auxiliary proteins 2. The receptor undergoes conformational changes upon glutamate binding, opening the cation channel and converting chemical signals to electrical impulses 3. GRIA2 expression patterns are cell-type specific, with lower expression in parvalbumin-positive interneurons contributing to their calcium-permeable AMPARs and reduced feature selectivity 4. Disease relevance is significant, as de novo heterozygous GRIA2 mutations cause neurodevelopmental disorders including intellectual disability, autism spectrum disorders, and epilepsy 1. Both gain-of-function and loss-of-function mutations have been identified, with specific variants at position Gly792 causing severe developmental delays and treatment-resistant epilepsy 5. These findings establish GRIA2 as a critical gene for normal neurodevelopment and synaptic function.